Long-term remission of an advanced recurrent endometrial cancer in a heavily pretreated patient using a combined regimen with bevacizumab and metronomic cyclophosphamide

Anti-Cancer Drugs

Volumn 22, Issue 8, 2011, Pages 822-824

  Reinhardt, Judith ^a   Schott, Sarah ^a   Mayer, Christine ^a   Sohn, Christof ^a   Eichbaum, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

drug therapy; endometrial carcinoma; palliative treatment

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TOPOTECAN;

ABDOMINAL DISCOMFORT; ABDOMINAL HYSTERECTOMY; ADULT; ADVANCED CANCER; ARTICLE; ASCITES; CANCER GROWTH; CANCER INFILTRATION; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CARCINOMATOUS PERITONITIS; CASE REPORT; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PELVIS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SALPINGOOOPHORECTOMY; SALVAGE THERAPY; TRANSVAGINAL ECHOGRAPHY; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CYCLOPHOSPHAMIDE; ENDOMETRIAL NEOPLASMS; FATIGUE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SALVAGE THERAPY; TIME FACTORS;

EID: 80051549823     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328344c0b9     Document Type: Article

References (8)

1. Van Wijk FH, Van der Burg MEL, Burger CW, Vergote I, Van Doorn HC. Management of recurrent endometrioid endometrial cancer: an overview. Int J Gynecol Cancer 2009; 19:314-320.
2. Ray M, Fleming G. Management of advanced-stage and recurrent endometrial cancer. Semin Oncol 2009; 36:145-154.
3. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007; 25:2902-2908. (Pubitemid 47123154)
4. Aghajanian C, Sill MW, Darcy K, Greer B, McMeekin DS, Rose PG, et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) Study. J Clin Oncol (Meeting Abstracts) 2009; 27:5531.
5. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006; 102:140-144. (Pubitemid 44056265)
6. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wie DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26:76-82.
7. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007; 13:7487-7495.
8. Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007; 27:3525-3528. (Pubitemid 47607497)